| abstract |
Many thalidomide metabolites with excellent anti-angiogenic properties are currently being isolated and identified. In addition, thalidomide analogs that mimic the effects of isolated and identified active thalidomide metabolites, and variants of such thalidomide analogs, have been developed. Such thalidomide analog compounds have increased efficacy in inhibiting unwanted angiogenesis without the undesirable effects of thalidomide administration. |